Comment on “External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension”

Robin Condliffe, Kris Bauchmuller, Jennifer Southern, David G. Kiely, Gary H. Mills


This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
To the Editor

We were very interested to read “External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension” by MVF Garcia and colleagues.¹ They have assessed our previously proposed predictive score for outcomes in medically-decompensated pulmonary hypertension (PH) patients: the OPALS score (oxygen (SpO2/FiO2) ≤ 185; platelets ≤ 196×10⁹·L⁻¹; age ≥ 37.5 years; lactate ≥ 2.45 mmol·L⁻¹; sodium ≤ 130.5 mmol·L⁻¹) in 74 PH patients. Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78).² Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R² = 0.97). The OPALS score therefore appears to be a promising PH-specific tool for predicting outcomes in medically-decompensated patients. Further work is, however, needed to compare its accuracy and utility compared with other ICU scoring systems and PH risk-stratification tools, and to assess its responsiveness to changing clinical severity during patients’ ICU admission.

Robin Condliffe¹,², Kris Bauchmuller³, Jennifer Southern³, David G Kiely¹,² and Gary H Mills³,⁴

Affiliations: ¹ Sheffield Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. ² Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. ³ Dept of Critical Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. ⁴ University of Sheffield, Sheffield, UK.

Corresponding author

Dr Robin Condliffe

Sheffield Pulmonary Vascular Disease Unit

Royal Hallamshire Hospital

Sheffield

S10 2JF

UK

robin.condliffe@nhs.net